微创医疗（00853.HK）今日盘中大涨5.2%，引发市场广泛关注。截至发稿，该股报9.01港元。
消息面上，微创医疗昨日晚间公告称，公司董事会正考虑一项关于策略重组集团心律管理（CRM）业务的不具约束力建议。根据该建议，待与有兴趣人士进一步磋商后，CRM业务将与微创心通（02160.HK）的业务合并。
公司表示，此次业务合并有多重战略意义。首先，将有助于建立一个强大的心脏病产品平台，提供从CRM的起搏器、除颤器到结构性心脏病的TAVI、LAA等全面的产品组合，提升集团的全球市场开发能力。其次，可以共享国际营销及销售渠道，为两项业务创造协同效应。最后，将心脏病产品平台的多元化产品及产品管线推向国际市场，有望提升国际资本市场对两项业务相关价值及增长潜力的认可。市场普遍认为，此次战略重组将有利于微创医疗整合资源、提升竞争力，并为公司及相关持份者创造长远价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.